Coherus BioSciences, Inc. (CHRS) AI Stock Analysis

Coherus BioSciences, Inc. is a biopharmaceutical company specializing in biosimilars and immuno-oncology therapies, operating primarily in the United States. Established in 2010 and based in Redwood City, California, the company markets its flagship product, UDENYCA, a biosimilar to Neulasta. Its pipeline features biosimilar candidates referencing Humira, Avastin, and Lucentis, including CHS-1420 and ranibizumab. Additionally, Coherus advances proprietary therapies such as Toripalimab, an anti-PD-1 antibody developed for second-line melanoma in China. Strategic collaborations with partners including Selexis SA, AbbVie, Inc., Pfizer, Inc., Bioeq AG, Innovent Biologics, and Junshi Biosciences support its therapeutic development programs.

Coherus experienced substantial top-line volatility over recent years, recording a 5-year revenue CAGR of -38.4% from FY2020 to FY2025. Annual revenue peaked at $267.0M in FY2024 before dropping 84.2% to $42.2M in FY2025, alongside an operating margin of -425.7% and a net loss of -$170.3M. While FY2024 generated net income of $28.5M, trailing twelve-month revenue totaled $50.9M with an operating margin of -226.0% and an eps_ttm of -$1.25. For the latest quarter ended June 30, 2026, quarterly revenue rose 39.5% year-over-year, while quarterly earnings growth dropped 75.5%.

As of June 30, 2026, Coherus reported cash and short-term investments of $105.3M against total debt of $37.7M, yielding net cash of $67.6M. The company maintains total assets of $191.2M and shareholders' equity of $60.8M, supported by a current ratio of 1.77 and a debt-to-equity ratio of 0.62. In FY2025, operating cash flow and free cash flow were both -$138.5M, while R&D expense stood at $105.0M. Additionally, the company expanded its share count by 101.5% over the past 5 years.

Coherus trades at a market capitalization of $153.0M and an enterprise value of $128.2M. The stock has a forward P/E of 41.2x, higher than the 17.3x forward P/E median of its US-listed Healthcare peers. Its price-to-sales multiple of 3.0x sits below the peer median of 4.1x, while its EV-to-EBITDA stands at 3.5x compared to the peer median of 12.0x. Over the past year, CHRS fell 42.1%, while the S&P 500 (SPY) gained 16.8%. Over 5 years, CHRS dropped 94.2% versus an 83.0% gain for SPY.

Wall Street coverage consists of 4 Strong Buy, 1 Buy, and 1 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target of $7.75 implies an upside of 682.8% over the last close of $0.99. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $60.8M and an EPS of -$0.85, reflecting 37.1% EPS growth. Over the last four quarters, the company beat EPS estimates 1 time. The next scheduled earnings date is November 5, 2026.

This page is an AI-written research summary of Coherus BioSciences, Inc. (CHRS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CHRS income statement, CHRS balance sheet, CHRS key metrics, CHRS analyst forecast, CHRS chart. See the CHRS stock overview for the latest quote and news.